Singapore markets closed

Straits Times Index
3,331.70
+5.42(+0.16%)
S&P 500
5,455.61
-13.69(-0.25%)
Dow
38,989.97
-122.19(-0.31%)
Nasdaq
17,689.80
-27.85(-0.16%)
Bitcoin USD
61,620.38
+616.66(+1.01%)
CMC Crypto 200
1,274.81
-8.97(-0.70%)

GSK Jun 2024 44.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0100

0.0000

(0.00%)

As of 02:46PM EDT. Market open.

Loading interactive chart…

The Telegraph
Britain snubs GSK in favour of US pharma giant for RSV vaccine
The NHS has turned to US drugs giant Pfizer over its British rival GSK for vaccines against Respiratory Syncytial Virus (RSV), the winter infection known as the “silent killer” of the elderly.
The Telegraph
The $3bn crisis casting a shadow over Dame Emma Walmsley’s GSK
As Dame Emma Walmsley stood up to deliver GSK’s latest set of results last month, she was brimming with confidence. This was “another excellent” period, she said, with sales and profits at the company booming.
Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk